Page last updated: 2024-10-29

ketoconazole and Central Serous Retinopathy

ketoconazole has been researched along with Central Serous Retinopathy in 1 studies

1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to evaluate a possible effect of systemic ketoconazole on visual acuity (VA) and retinal thickness in patients with acute central serous chorioretinopathy (CSCR)."9.14Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. ( Eter, N; Golshahi, A; Holz, FG; Klingmüller, D, 2010)
"The aim of this study was to evaluate a possible effect of systemic ketoconazole on visual acuity (VA) and retinal thickness in patients with acute central serous chorioretinopathy (CSCR)."5.14Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. ( Eter, N; Golshahi, A; Holz, FG; Klingmüller, D, 2010)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Golshahi, A1
Klingmüller, D1
Holz, FG1
Eter, N1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170]Phase 216 participants (Actual)Interventional2015-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for ketoconazole and Central Serous Retinopathy

ArticleYear
Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study.
    Acta ophthalmologica, 2010, Volume: 88, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Central Serous Chorioretinopathy; Female; Fluores

2010